ReviewCurrent treatment options in oncology2010
Treatment options for surgically resectable gastric cancer.
Review in Current treatment options in oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients.BMC cancer · 2024Article
- Prognostic prediction and treatment options for gastric signet ring cell carcinoma: a SEER database analysis.Frontiers in oncology · 2024Article
- Article
- Radical Gastrectomy: Still the Gold Standard Treatment for Gastric Cancer-Our Experience from a Tertiary Care Center from Northeast India.Indian journal of surgical oncology · 2020Article
- The principles of the surgical management of gastric cancer.International journal of surgery. Oncology · 2017Article
- Regulation of osmolality for cancer treatment.The journal of physiological sciences : JPS · 2017Review
- Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer.OncoTargets and therapy · 2015Article
- High-Throughput Sequencing of miRNAs Reveals a Tissue Signature in Gastric Cancer and Suggests Novel Potential Biomarkers.Bioinformatics and biology insights · 2015Article
- Metabolomic studies of human gastric cancer: review.World journal of gastroenterology · 2014Review
- Overexpression of Nedd9 is a prognostic marker of human gastric cancer.Medical oncology (Northwood, London, England) · 2014Article
- Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma.Radiology and oncology · 2014Article
- Efficacy of a hypotonic treatment for peritoneal dissemination from gastric cancer cells: an in vivo evaluation.BioMed research international · 2014Article
- Clinical implications of DLL4 expression in gastric cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy.World journal of surgical oncology · 2013Article
- Urine Metabolite Profiling of Human Colorectal Cancer by Capillary Electrophoresis Mass Spectrometry Based on MRB.Gastroenterology research and practice · 2012Article
- Ion chromatography based urine amino Acid profiling applied for diagnosis of gastric cancer.Gastroenterology research and practice · 2012Article
- Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma.Annals of surgical oncology · 2011Article
- Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry.World journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.